OS Therapies confirms 3-year overall survival benefit in Phase 2b trial for osteosarcoma with lung metastasis
OSTX OS Therapies Inc
$1.49 -6.88%
View chart & analysis → - 1OS Therapies announced statistically significant final 3-year overall survival benefits in a Phase 2b trial for patients with osteosarcoma and lung metastasis.
- 2The final 3-year overall survival rate for patients treated with OST-HER2 was 72.7%, higher than the 45.8% in the control group.
- 3The World Health Organization has approved the brand name 'Herlystic' for OST-HER2.
So what's the key point?
OS Therapies confirmed treatment effectiveness for patients whose cancer has spread to the lungs. The 3-year survival rate for treated patients was 72.7%, showing a positive result.
Source Newsfile · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.